Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy

Ophthalmology

Volumn 122, Issue 2, 2015, Pages 367-374

  Ip, Michael S ^a   Domalpally, Amitha ^a   Sun, Jennifer K ^b   Ehrlich, Jason S ^c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFECT; EYE PHOTOGRAPHY; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA FOVEA; RISK FACTOR; TREATMENT DURATION; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; CROSSOVER PROCEDURE; DISEASE COURSE; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MALE; MIDDLE AGED; MULTICENTER STUDY; OPTICAL COHERENCE TOMOGRAPHY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RETINAL NEOVASCULARIZATION; SEVERITY OF ILLNESS INDEX;

ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CROSS-OVER STUDIES; DIABETIC RETINOPATHY; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; RETINAL NEOVASCULARIZATION; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84921518376     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2014.08.048     Document Type: Article

References (25)

1. Eye Diseases Prevalence Research Group The prevalence of diabetic retinopathy among adults in the United States Arch Ophthalmol 122 2004 552 563
2. Early Treatment Diabetic Retinopathy Study Research Group Grading diabetic retinopathy from stereoscopic color fundus photographs-an extension of the modified Airlie House classification: ETDRS report number 10 Ophthalmology 98 suppl 1991 786 806
3. M.S. Ip, A. Domalpally, and J.J. Hopkins Long-term effects of ranibizumab on diabetic retinopathy severity and progression Arch Ophthalmol 130 2012 1145 1152
4. P.A. Pearson, T.L. Comstock, and M. Ip Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial Ophthalmology 118 2011 1580 1587
5. N. Chaturvedi, M. Porta, R. Klein DIRECT Programme Study Group Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials Lancet 372 2008 1394 1402
6. A.K. Sjolie, R. Klein, M. Porta DIRECT Programme Study Group Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial Lancet 372 2008 1385 1393
7. Diabetic Retinopathy Clinical Research Network, M.J. Elman, H. Qin, and L.P. Aiello Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results Ophthalmology 119 2012 2312 2318
8. Diabetic Retinopathy Clinical Research Network (DRCR.net) Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema Arch Ophthalmol 127 2009 245 251
9. L.P. Aiello, R.L. Avery, and P.G. Arrigg Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders N Engl J Med 331 1994 1480 1487
10. T. Qaum, Q. Xu, and A.M. Joussen VEGF-initiated blood-retinal barrier breakdown in early diabetes Invest Ophthalmol Vis Sci 42 2001 2408 2413
11. M.J. Tolentino, J.W. Miller, and E.S. Gragoudas Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate Ophthalmology 103 1996 1820 1828
12. A.P. Adamis, J.W. Miller, and M.T. Bernal Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy Am J Ophthalmol 118 1994 445 450
13. L.C. Groop, H. Teir, and S. Koskimies Risk factors and markers associated with proliferative retinopathy in patients with insulin-dependent diabetes Diabetes 35 1986 1397 1403
14. R. Klein, S.E. Moss, and B.E. Klein Is gross proteinuria a risk factor for the incidence of proliferative diabetic retinopathy? Ophthalmology 100 1993 1140 1146
15. M.D. Davis, M.R. Fisher, R.E. Gangnon Early Treatment Diabetic Retinopathy Study Research Group Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study report #18 Invest Ophthalmol Vis Sci 39 1998 233 252
16. M. Janghorbani, R.B. Jones, and S.P. Allison Incidence of and risk factors for proliferative retinopathy and its association with blindness among diabetes clinic attenders Ophthalmic Epidemiol 7 2000 225 241
17. M. Porta, A.K. Sjoelie, N. Chaturvedi EURODIAB Prospective Complications Study Group Risk factors for progression to proliferative diabetic retinopathy in the EURODIAB Prospective Complications Study Diabetologia 44 2001 2203 2209
18. L. Zhang, G. Krzentowski, A. Albert, and P.J. Lefebvre Risk of developing retinopathy in Diabetes Control and Complications Trial type 1 diabetic patients with good or poor metabolic control Diabetes Care 24 2001 1275 1279
19. G. Leese Longitudinal study examining the risk factors for proliferative retinopathy and maculopathy in type-I diabetes: the Royal College of Physicians of Edinburgh Diabetes Register Group Eye (Lond) 18 2004 814 820
20. Q.D. Nguyen, D.M. Brown, D.M. Marcus RISE and RIDE Research Group Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE Ophthalmology 119 2012 789 801
21. N.M. Bressler, A.R. Edwards, R.W. Beck Diabetic Retinopathy Clinical Research Network Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation Arch Ophthalmol 127 2009 1566 1571
22. P.A. Campochiaro, C.C. Wykoff, and H. Shapiro Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients with diabetic macular edema Ophthalmology 121 2014 1783 1789
23. L. Yu, X.H. Liang, and N. Ferrara Comparing protein VEGF inhibitors: In vitro biological studies Biochem Biophys Res Commun 408 2011 276 281
24. L. Xu, T. Lu, and L. Tuomi Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach Invest Ophthalmol Vis Sci 54 2013 1616 1624
25. D. Gologorsky, A. Thanos, and D. Vavvas Therapeutic interventions against inflammatory and angiogenic mediators in proliferative diabetic retinopathy Mediators Inflamm 2012 2012 629452